Infectious disease
President Biden announced updates to the “Test to Treat” initiative that will allow people to get tested for COVID at a pharmacy and receive a treatment round of Pfizer’s Paxlovid at no cost.
The study, which has yet to be peer-reviewed, found the Pfizer-BioNTech vaccine was only about 12% effective for children ages 5 to 11 years against the Omicron variant.
The FDA lifts its clinical hold on Ocugen’s COVID-19 vaccine, and Ocugen announces a clinical trial for the treatment of inherited retinal diseases.
On Monday, Arbutus and Genevant filed a lawsuit against Moderna challenging patent infringement.
Three new studies have been released—but not yet peer-reviewed—that support the wet market theory relating to COVID-19.
It is unknown whether tightening economic sanctions will limit Russia’s ability to ship its vaccines to areas that do not have strong manufacturing capabilities.
The Centers for Disease Control and Prevention (CDC) revised its recommendations on wearing masks indoors to protect against COVID-19.
The latest EUA adjustment was based on findings that Evusheld might not be as active against certain subvariants of Omicron, but it could be if the dosage is increased.
The FDA places holds, companies receive clearance for new studies and Pharma giants release new data in last week’s clinical trial news.
Not only is this the first approval for a plant-based vaccine, it’s also the first approval for GSK’s adjuvant.
PRESS RELEASES